Gesine Kogler

Prof. Dr. Gesine Kogler

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Cells
Verified
Journal Article
Open access
PDF file
MOMeryem Ouzin
Meryem Ouzin
GKGesine Kogler
Gesine Kogler
Mesenchymal stromal cells nowadays emerge as a major player in the field of regenerative medicine and translational research. They constitute, with their derived products, the most frequently used cell type in different therapies. However, their heterogeneity, including different subpopulations, the anatomic source of isolation, and high donor-to-donor variability, constitutes a major controversial issue that affects their use in clinical applications. Furthermore, the intrinsic and extrinsic molecular mechanisms underlying their self-renewal and fate specification are still not completely elucidated. This review dissects the different heterogeneity aspects of the tissue source associated with a distinct developmental origin that need to be considered when generating homogenous products before their usage for clinical applications.

21 April 2015 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
SLStefanie Liedtke
Stefanie Liedtke
SBSophie Biebernick
Sophie Biebernick
TRTeja Falk Radke
Teja Falk Radke
DSDaniela Stapelkamp
Daniela Stapelkamp
CCCarolin Coenen
Carolin Coenen
GKGesine Kogler
Gesine Kogler
Comprehensive analyses comparing individual DNA damage response (DDR) of induced pluripotent stem cells (iPSCs) with neonatal stromal cells with respect to their developmental age are limited. The imperative necessity of providing developmental age-matched cell sources for meaningful toxicological drug safety assessments in replacement of animal-based testing strategies is evident. Here, DDR after radiation or treatment with N-methyl-N-nitrosurea (MNU) was determined in iPSCs compared with neonatal and bone marrow stromal cells. Neonatal and adult stromal cells showed no significant morphologically detectable cytotoxicity following treatment with 1 Gy or 1 mM MNU, whereas iPSCs revealed a much higher sensitivity. Foci analyses revealed an effective DNA repair in stromal cell types and iPSCs, as reflected by a rapid formation and disappearance of phosphorylated ATM and γH2AX foci. Furthermore, quantitative polymerase chain reaction analyses revealed the highest basic expression level of DDR and repair-associated genes in iPSCs, followed by neonatal stromal cells and adult stromal cells with the lowest expression levels. In addition, the influence of genotoxic stress prior to and during osteogenic differentiation of neonatal and adult stromal cells was analyzed applying common differentiation procedures. Experiments presented here suggest a developmental age-dependent basic expression level of genes involved in the processing of DNA damage. In addition a differentiation-dependent downregulation of repair genes was observed during osteogenesis. These results strongly support the requirement to provide adequate cell sources for toxicological in vitro drug testing strategies that match to the developmental age and differentiation status of the presumptive target cell of interest. Significance: The results obtained in this study advance the understanding of DNA damage processing in human neonatal stromal cells as compared with adult stromal cells and induced pluripotent stem cells (iPSCs). The data suggest developmental age-dependent differences in DNA damage repair capacity. In iPSCs (closest to embryonic stem cells), the highest expression level of DNA damage response and repair genes was found, followed by neonatal stromal cells and adult stromal cells with the lowest overall expression. In addition, a differentiation-dependent downregulation of repair capacity was observed during osteogenic differentiation in neonatal stromal cells. Notably, the impact of genotoxic stress on osteogenic differentiation depended on the time the genotoxic insult took place and, moreover, was agent-specific. These results strongly support the necessity of offering and establishing adequate cell sources for informative toxicological testing matching to the developmental age and differentiation status of the respective cell of interest.

1 December 2003 in Acta Ophthalmologica Scandinavica
Verified
Journal Article
Open access
PDF file
TRThomas Reinhard
Thomas Reinhard
DBDaniel Böhringer
Daniel Böhringer
JEJürgen Enczmann
Jürgen Enczmann
GKGesine Kogler
Gesine Kogler
PWPeter Wernet
Peter Wernet
RSRainer Sundmacher
Rainer Sundmacher
: Objective:  Chronic endothelial cell loss of the graft is very common after penetrating keratoplasty. The aetiology of this is unknown. Clinically, non‐identifiable immune reactions have been suspected. Recently, we were able to demonstrate that proper human leucocyte antigen (HLA) matching is a suitable means to reduce classical immune reactions in normal risk keratoplasty patients. In this study, we therefore investigated whether HLA‐matched grafts also experience less chronic endothelial cell loss.Methods:  A homogenous group of 223 normal risk keratoplasty patients was divided into six groups with different degrees of HLA matching (group 1 with unknown HLA data, group 2 with up to two mismatches, group 3 with three mismatches, group 4 with four mismatches, group 5 with five mismatches and group 6 with six mismatches on the HLA A, B, DR loci). All serological HLA A, B, C and all moleculargenetic HLA DRB, DRQB typings of donors and recipients were performed in a single laboratory accredited by the American Society for Histocompatibility and Immunogenetics. Only patients with at least three postoperative endothelial cell density values were included in the study. The slopes of the regression lines for each individual scatterplot of endothelial cell density values plotted against postoperative time (linear regression, lost cells/mm2/day), and after logarithmic transformation (exponential regression, annual relative loss of cells) were evaluated, respectively.Results:  There were no statistically significant differences between the six groups.Conclusion:  Whereas proper HLA matching at present standards is already a suitable means to reduce identifiable immune reactions and to prolong graft survival even in normal risk keratoplasty patients, the same HLA matching procedures are not effective in reducing the extent of chronic endothelial cell loss. For several reasons this does not yet exclude, however, the possibility that the underlying cause of chronic endothelial cell loss is immunological.

20 July 2020 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
SLStefanie Liedtke
Stefanie Liedtke
LKLutz Korschgen
Lutz Korschgen
JKJanine Korn
Janine Korn
ADAlmuth Duppers
Almuth Duppers
GKGesine Kogler
Gesine Kogler
Background: Based on a synergistic consortium, the cord blood (CB) bank Düsseldorf was responsible for the selection of HLA‐homozygous (HLA‐h) donors, contacting/re‐consenting the mothers, Good Manufacturing Practice (GMP)‐grade CD34+ enrichment, followed by short‐term expansion of CD34+ cells and qualification of the resulting CD34+ population as advanced therapy medicinal product (ATMP)‐starting material. Among 20 639 licensed Düsseldorf cord blood units (CBUs), 139 potential HLA‐h donors were identified with the most frequent 10 German haplotypes. 100% of the donors were contacted, and for 47·5%, consent was obtained. HLA‐A, ‐B, ‐C, ‐DR, ‐DQ and ‐DP were determined by sequencing.Methods: Thawing/washing of the CBUs was performed in the presence of Volulyte/HSA with Sepax®, CD34+ selection by automated CliniMACS®‐system (Miltenyi), expansion with qualified GMP‐grade cytokines and media in the GMP facility.Results: Here, we specify minimal criteria (≥5 x 105 viable CD34+‐count, ≥80% CD34+‐purity and ≥70% viability) and confirm that n = 10 CB units (max storage time 16 years) could be qualified for an ATMP starting material. The mean fold change expansion of isolated CD34+ cells at Day 3/4 (d3/4) was 3·38 ± 3·02 with a mean purity of 86·90 ± 10·38% and a high viability of 96·07 ± 4·72%.Conclusion: As of March 2019, approval was obtained by the Bezirksregierung Düsseldorf for the GMP‐compliant production. The production of HLA‐homozygous expanded CD34+ cells from cryopreserved CB under European ATMP regulations presented here describes the successful clinical translation and implementation of a qualified manufacturing process. This approach considers the main obstacle of rejection of transplanted cells (due to the immunological HLA barrier) by preselection of HLA‐homozygous transplants.

16 September 2013 in Stem Cells International
Verified
Journal Article
Open access
PDF file
JBJulia Bosch
Julia Bosch
AHAmelie Pia Houben
Amelie Pia Houben
THTatiana Hennicke
Tatiana Hennicke
RDRené Deenen
René Deenen
KKKarl Köhrer
Karl Köhrer
GKGesine Kogler
Gesine Kogler
With regard to the bone-regenerative capacity, bone marrow stromal cells (BMSC) can still be termed the “gold standard.” Nevertheless, neonatal stromal cells from cord blood (CB) feature advantages concerning availability, immaturity, and proliferation potential. The detailed gene expression analysis and overexpression of genes expressed differentially provide insight into the inherent capacity of stromal cells. Microarray and qRT-PCR analyses revealed closely related gene expression patterns of two stromal cell populations derived from CB. In contrast to the CB-derived cell types, BMSC displayed high expression levels ofBSP,OSX,BMP4,OC, andPITX2. Lentiviral overexpression ofBSPbut not ofOSXin CB-cells increased the capacity to form a mineralized matrix.BMP4induced the secretion of proteoglycans during chondrogenic pellet culture and extended the osteogenic but reduced the adipogenic differentiation potential. BMSC revealed the typical osteogenic gene expression signature. In contrast, the CB-derived cell types exhibited a more immature gene expression profile and no predisposition towards skeletal development. The absence ofBSPandBMP4—which were defined as potential key players affecting the differentiation potential—in neonatal stromal cells should be taken into consideration when choosing a cell source for tissue regeneration approaches.

19 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RIRicarda Ising
Ricarda Ising
SWSandra Weinhold
Sandra Weinhold
SBSabrina Bianca Bennstein
Sabrina Bianca Bennstein
AZAlbert Zimmermann
Albert Zimmermann
ODOezer Degistirici
Oezer Degistirici
MUMarkus Uhrberg
Markus Uhrberg
Human cytomegalovirus (HCMV) is highly prevalent in most populations worldwide and has a major influence on shaping the human immune system. Natural killer (NK) cells are important antiviral effectors that adapt to HCMV infection by expansion of virus-specific effector/memory cells. The impact of HCMV infection on the development of NK cells and innate lymphoid cells (ILC) in general is less well understood. In this context, we have recently established a novel in vitro platform to study human NK cell development in a stem cell niche based on human bone marrow-derived mesenchymal stem cells (MSC). Here, the system was modified by infecting MSC with HCMV to study the influence of virus infection on NK/ILC development. We show that cord blood-derived hematopoietic progenitor cells are successfully differentiated into mature CD56+CD94+NKG2A+ NK cells on HCMV-infected MSC with significant higher anti-viral cytokine production compared to NK cells developing on non-infected MSC. Furthermore, the generation of ILC3, characterized by expression of the signature transcription factor RAR-related orphan receptor gamma (RORγt) and the production of IL-22, was strongly impaired by HCMV infection. These observations are clinically relevant, given that ILC3 are associated with protection from graft-versus-host disease (GvHD) following stem cell transplantation and HCMV reactivation in turn is associated with increased incidence of GvHD.